Biogen (NASDAQ: BIIB) Q3 2024 Earnings Call Oct 30, 2024, 8:30 a.m. ET ...

Here are some of the recent management changes that took place during the week: Biogen (NASDAQ:BIIB) said its Executive Vice ...

US Bancorp DE reduced its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 15.7% in the third quarter, according ...

Fintel reports that on October 31, 2024, Morgan Stanley downgraded their outlook for Biogen (NasdaqGS:BIIB) from Overweight ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB.

In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Biogen partners with Neomorph to develop molecular glue degraders for Alzheimer's and other diseases, offering up to $1.45B in payments.

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.

On Monday, Biogen Inc (BIIB) stock saw a decline, ending the day at $184.65 which represents a decrease of $-5.51 or -2.90% from the prior close of $190.16. The stock opened at $190.16 and touched a ...

Needham analyst Ami Fadia has maintained their bullish stance on BIIB stock, giving a Buy rating yesterday. Ami Fadia has given her Buy rating ...

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Ballentine Partners LLC lowered its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 54.1% in the 3rd quarter, according ...